CHIRON® RECOMBINANT PROTEINS
A LOCAL PARTNER IN THE SAN FRANCISCO BAY AREA
The biomanufacturing legacy of the Grifols campus in Emeryville, California, began with Chiron and Cetus in the 1980s, with innovative advancements in yeast expression, viral discovery and the development of PCR. Three decades of process development and manufacturing experience is the foundation of the business today at CHIRON® Recombinant Proteins.
CHIRON® Recombinant Proteins partners with companies interested in developing complex proteins into therapeutics, vaccines or diagnostics. Our state-of-the-art GMP biological manufacturing CMF facility located in the San Francisco Bay Area is well positioned to provide long-term, high-quality, commercial manufacturing of recombinant biologic drug substances to our customers, regardless of their global location. This location, in one of the major U.S. biotech hubs –– home to many emerging biotechnology companies lacking extensive internal development and manufacturing resources –– provides us with an opportunity to effectively serve a host of local customers.
CHIRON® Recombinant Proteins is staffed by highly experienced and talented people with diverse expertise and educational backgrounds within the field of biotechnology. Our staff welcomes the opportunity to have face-to-face visits with clients where new ideas can be discussed. With their significant tech transfer expertise and access to the state-of-the-art facilities and equipment within the CMF and new pilot plant, including R&D, process development and analytical laboratories, our scientists can rapidly identify solutions for our CDMO clients.
About GRIFOLS
Grifols is a global healthcare company founded in Barcelona in 1940, committed to improving the health and well-being of people around the world. We produce essential plasma medicines for patients to treat rare, chronic and, at times, life-threatening conditions. The company provides a comprehensive portfolio of solutions in transfusion medicine and also offers hospitals, pharmacies and healthcare professionals information and services that deliver efficient, expert medical care.
FEATURED PRODUCTS AND SERVICES
The Benefits of Partnering with CHIRON®
Chiron is ready to partner with you to support development of complex proteins into new therapeutics, diagnostics and vaccines.
Chiron has development and cGMP production capacity for recombinant proteins in yeast.
cGMP production of recombinant proteins made in E. coli is performed in Chiron’s new state-of-the-art facility.
Chiron excels in expressing complex, challenging proteins that don’t fit into a predefined program. Our scientists are creative and innovative applying new techniques to solve problems of yield, protein folding, purity, and more. The best projects are those that have never been done before and have the potential to change the view of medicine or manufacturing.
Chiron has analytical method development and testing to support all stages of product development and manufacturing.
Chiron supplies recombinant Human Immunodeficiency Virus (HIV) antigens including HIV-1, HIV-2 and HIV-1 Type O from the envelope and gag regions. These antigens are currently used in immunoassays that test blood donations worldwide as well as clinical testing of patients.
Chiron supplies recombinant antigens from the Core, NS3, NS4 and NS5 regions of the Hepatitis C Virus (HCV) genome. These antigens are currently used in immunoassays that test >60% of the blood donations worldwide as well as clinical testing of patients.
Chiron supplies recombinant Hepatitis B Virus (HBV) core antigen for immunoassay diagnostics. This antigen is used in immunoassays that test blood donations worldwide as well as clinical testing of patients.
Our HBV antigen is a licensed biologic with the FDA.
CONTACT INFORMATION
CHIRON® Recombinant Proteins
4560 Horton Street
Emeryville, CA 94608
UNITED STATES
Phone: 510-923-6540
Contact: Paul Magreta
FEATURED CONTENT
-
![Chiron-Image]( "Recombinant Proteins: Understanding 5 Key Process Development Challenges")
Once a company has demonstrated proof of concept, it is critical to consider process elements like scalability, sourcing raw materials, and GMP adherence.
-
![innovation]( "Innovation And Flexibility During The COVID-19 Pandemic")
The biopharma industry has been challenged to discover and develop new diagnostic tests, treatments, and vaccines to help resolve the pandemic. Learn how one CDMO embraces the challenge.
-
![Collaboration]( "Improve Biopharma Fermentation With Innovation, Collaboration")
Organizations developing products requiring fermentation often create custom processes from scratch, leaving room for inefficiencies, lost value, and, in the case of significant error, costly time delays.
-
![Grifols]( "Grifols Recombinant Protein CDMO")
Grifols Recombinant Protein CDMO, in Emeryville, California, produces recombinant proteins for therapeutics and diagnostics. With services ranging from concept to process development to GMP manufacturing, we look forward to partnering with you to bring your vision to life, together.
-
![Grifols]( "Leveraging A Biomanufacturing Legacy To Support New Business")
Seven diverse experts discuss how Grifols Recombinant Protein CDMO's legacy and recent investments support its future in providing recombinant protein CDMO services.
-
![Partners]( "Growing With A Flexible, Collaborative CDMO")
Choosing a CDMO that is agile, innovative, and exhibits a willingness to invest in new equipment, infrastructure and services will allow the innovator company and the CDMO to grow together.
-
![DIA Combination Products Conference]( "Explore Alternative Analytical Methods To Solve Process Challenges")
Successful and rapid analytical method development plays a key role in ensuring the development of robust processes to produce high-quality products.
-
![Quality-Lab-Picture]( "Quality Assurance And Your CDMO")
The result of regulatory compliance with quality standards is binary, but the processes employed to get there don't need to be rigid, inefficient, and expensive. Learn how innovation drives efficiencies.
-
![Grifols CMF pic]( "Grifols New Manufacturing Facility Provides Contract Development And Manufacturing Solutions For Recombinant Proteins")
Grifols' Consolidated Manufacturing Facility (CMF) is a flexible, multiproduct facility with available manufacturing capacity that created an opportunity to leverage their existing technical expertise and commitment to quality to provide contract services to biopharma companies as a recombinant protein CDMO and support the development of innovative therapies. We recently spoke with Paul Magreta at Grifols about their new $80 million manufacturing facility in Emeryville, California, and the CDMO Services they offer.
-
![Grifols Building]( "Grifols Achieves Key Milestone With FDA Approval Of The New Consolidated Manufacturing Facility (CMF) For Production Of Recombinant Proteins")
Emeryville, CA - Grifols (MCE: GRF, MCE: GRF.P andNASDAQ: GRFS), a global healthcare company with a history of more than 75 years of improving people's health and well-being and a leader in the development of innovative diagnostic solutions, recently received approval from the U.S. Food & Drug Administration to relocate existing immunodiagnostic manufacturing operations to a new Consolidated Manufacturing Facility (CMF) in Emeryville, California
-
![Grifols]( "Optimizing CDMO Technical Transfer")
Learn how a CDMO helps biopharma organizations predict and mediate technical transfer risks before they become costly, time-consuming problems.
